Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis
Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd....
Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd....
Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide...
Ab&b Bio-Tech Co.,Ltd. (HKG: 2627) announced that the National Medical Products Administration (NMPA) has granted...
Sanofi (NASDAQ: SNY) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human...
China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...
Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...
The Center for Drug Evaluation (CDE) is seeking industry feedback on the 103rd batch of...
Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ: AMGN) for...
Chiesi Group announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended...
Novo Nordisk (NYSE: NVO) announced that Zhou Xiaping, Senior Vice President and President of Greater China,...
China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...
Zhaoke Ophthalmology (HKG: 6622) announced that its UK partner Tenpoint Therapeutics has received FDA clearance...
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the National Medical Products Administration (NMPA) has approved...
AstraZeneca (AZ, NASDAQ: AZN) announced a plan to invest RMB 100 billion (USD 14.4 billion) :in China by 2030 to...
Thermo Fisher Scientific Inc. (NYSE: TMO) reported fourth‑quarter revenue of $12.21 billion , up 7% year‑on‑year (YOY),...
TYK Medicines, Inc. (HKG: 2410) announced that its Category 1 drug asandeutertinib (TY‑9591), a third‑generation EGFR...
Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK) reported third‑quarter fiscal 2025 revenue of 3,411.2 billion yen (USD 22.17 billion), down...
Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong...
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that a supplementary Biologics License Application (sBLA)...